Results

1–10 of 255 results for Anti-VEGF

Expert Panel: Faricimab and Aflibercept 8 mg in AMD
John T. Thompson, MD
Andrew A. Moshfeghi, MD, MBA, FASRS
Manjot K Gill, MD, FASRS
Christina Y Weng, MD, MBA, FASRS
Ferhina S Ali, MD, MPH
Ian Pearce, MB ChB BSc FRCOPHTH
Annual Meeting Talks
2024
Expert Panel: Socioeconomics
Linda A. Lam, MD, MBA, FASRS
Ella H Leung, MD
Mohsin H. Ali, MD
Hasenin Al-khersan, MD
Miguel A. Busquets, MD, FACS
Annual Meeting Talks
2024
Assessment on Pre-to-Post Switching Efficacy and Safety of SB15 (Proposed Aflibercept Biosimilar): Post Hoc Analysis of a Phase 3 Clinical Trial
Srinivas Reddy Sadda, MD
Annual Meeting Talks
2024
Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Annual Meeting Talks
2024
Long-Term Outcome of Diabetic Eyes With Vitreous Hemorrhage in an Urban Safety-Net Hospital
Hossein Ameri, MD, PhD, FRCSI, MRCOphth
Annual Meeting Talks
2024
Durability of Combination Therapy of Sozinibercept, an Anti-VEGF-C/D 'Trap' With Ranibizumab in nAMD or Aflibercept in DME
Nathan C. Steinle, MD
Annual Meeting Talks
2024
Association Between Provider Anti-VEGF Injection Rates and Visual Outcome In Eyes With Neovascular Age-Related Macular Degeneration
Michael M. Lai, MD, PhD
Annual Meeting Talks
2024
Baseline Characteristics Associated With Catastrophic Vision Loss Due to Subretinal Hemorrhage in Patients Undergoing Treatment for Neovascular Macular Degeneration
Eric W Schneider, MD
Annual Meeting Talks
2024
Subretinal Delivery of Investigational ABBV-RGX-314 for Neovascular Age-Related Macular Degeneration: A Phase II Pharmacodynamic Study
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2024